Question · Q4 2025
Michael Gee asked about Amgen's overall obesity portfolio, including MariTide, potential combinations, and other assets like AMG 513, seeking management's view on how this portfolio will play out in the market.
Answer
Robert Bradway, CEO, and James Bradner, EVP of Research and Development, discussed MariTide's broad development across multiple indications, the progression of AMG 513 in Phase 1, and a pipeline of both incretin-based and non-incretin-based, injectable and oral preclinical programs, indicating a broad competitive strategy in the obesity field.
Ask follow-up questions
Fintool can predict 
AMGN's earnings beat/miss a week before the call
